Molecular diagnostics is a technique used to detect the presence of and identify genetic materials and proteins associated with specific health conditions and diseases, and infectious agents in body fluids such as blood, urine, or sputum. Molecular diagnostics for infectious disease testing is used by hospitals, academics institutions, laboratories, and others.
The global market for Molecular Diagnostics Infectious Disease Testing was estimated to be worth US$ 5629 million in 2023 and is forecast to a readjusted size of US$ 8304.9 million by 2030 with a CAGR of 7.1% during the forecast period 2024-2030
Molecular diagnostics is a technology that diagnoses diseases by detecting and analyzing biomarkers (such as DNA, RNA, proteins, etc.). In infectious disease testing, molecular diagnostics can be used to detect the nucleic acid sequences of pathogens to determine whether infection is viral or bacterial. Traditional infectious disease detection methods usually require tedious culture and detection steps, while molecular diagnostics can extract nucleic acids directly from samples and perform rapid and accurate detection. This method has the advantages of high sensitivity, high specificity and rapid response, which can detect the disease at an early stage, avoid the spread of the disease, and better control the outbreak of infectious diseases. At present, molecular diagnosis has been widely used in the detection of various infectious diseases, such as AIDS, hepatitis, tuberculosis, influenza, new coronavirus, etc., providing important support and help for the prevention and control of infectious diseases.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Molecular Diagnostics Infectious Disease Testing, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Molecular Diagnostics Infectious Disease Testing by region & country, by Type, and by Application.
The Molecular Diagnostics Infectious Disease Testing market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Molecular Diagnostics Infectious Disease Testing.
Market Segmentation
By Company
Abbott Laboratories
BD
²ú¾±´Ç²Ñé°ù¾±±ð³Ü³æ
Thermo Fisher Scientific
F. Hoffmann-La Roche
Siemens AG
Veridex
Luminex
GenMark Diagnostics
Qiagen NV
Genomix Biotech
BioTheranostics
GenMark Diagnostics
Segment by Type:
Bacterial Infectious Disease Testing
Viral Infectious Disease Testing
Parasitic Infectious Disease Testing
Segment by Application
Hospital
Laboratory Research
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Molecular Diagnostics Infectious Disease Testing manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Molecular Diagnostics Infectious Disease Testing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Molecular Diagnostics Infectious Disease Testing in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Market Overview
1.1 Molecular Diagnostics Infectious Disease Testing Product Introduction
1.2 Global Molecular Diagnostics Infectious Disease Testing Market Size Forecast
1.3 Molecular Diagnostics Infectious Disease Testing Market Trends & Drivers
1.3.1 Molecular Diagnostics Infectious Disease Testing Industry Trends
1.3.2 Molecular Diagnostics Infectious Disease Testing Market Drivers & Opportunity
1.3.3 Molecular Diagnostics Infectious Disease Testing Market Challenges
1.3.4 Molecular Diagnostics Infectious Disease Testing Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Molecular Diagnostics Infectious Disease Testing Players Revenue Ranking (2023)
2.2 Global Molecular Diagnostics Infectious Disease Testing Revenue by Company (2019-2024)
2.3 Key Companies Molecular Diagnostics Infectious Disease Testing Manufacturing Base Distribution and Headquarters
2.4 Key Companies Molecular Diagnostics Infectious Disease Testing Product Offered
2.5 Key Companies Time to Begin Mass Production of Molecular Diagnostics Infectious Disease Testing
2.6 Molecular Diagnostics Infectious Disease Testing Market Competitive Analysis
2.6.1 Molecular Diagnostics Infectious Disease Testing Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Molecular Diagnostics Infectious Disease Testing Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Molecular Diagnostics Infectious Disease Testing as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Bacterial Infectious Disease Testing
3.1.2 Viral Infectious Disease Testing
3.1.3 Parasitic Infectious Disease Testing
3.2 Global Molecular Diagnostics Infectious Disease Testing Sales Value by Type
3.2.1 Global Molecular Diagnostics Infectious Disease Testing Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Molecular Diagnostics Infectious Disease Testing Sales Value, by Type (2019-2030)
3.2.3 Global Molecular Diagnostics Infectious Disease Testing Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Laboratory Research
4.2 Global Molecular Diagnostics Infectious Disease Testing Sales Value by Application
4.2.1 Global Molecular Diagnostics Infectious Disease Testing Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Molecular Diagnostics Infectious Disease Testing Sales Value, by Application (2019-2030)
4.2.3 Global Molecular Diagnostics Infectious Disease Testing Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Molecular Diagnostics Infectious Disease Testing Sales Value by Region
5.1.1 Global Molecular Diagnostics Infectious Disease Testing Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Molecular Diagnostics Infectious Disease Testing Sales Value by Region (2019-2024)
5.1.3 Global Molecular Diagnostics Infectious Disease Testing Sales Value by Region (2025-2030)
5.1.4 Global Molecular Diagnostics Infectious Disease Testing Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Molecular Diagnostics Infectious Disease Testing Sales Value, 2019-2030
5.2.2 North America Molecular Diagnostics Infectious Disease Testing Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Molecular Diagnostics Infectious Disease Testing Sales Value, 2019-2030
5.3.2 Europe Molecular Diagnostics Infectious Disease Testing Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Molecular Diagnostics Infectious Disease Testing Sales Value, 2019-2030
5.4.2 Asia Pacific Molecular Diagnostics Infectious Disease Testing Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Molecular Diagnostics Infectious Disease Testing Sales Value, 2019-2030
5.5.2 South America Molecular Diagnostics Infectious Disease Testing Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Molecular Diagnostics Infectious Disease Testing Sales Value, 2019-2030
5.6.2 Middle East & Africa Molecular Diagnostics Infectious Disease Testing Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Molecular Diagnostics Infectious Disease Testing Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Molecular Diagnostics Infectious Disease Testing Sales Value
6.3 United States
6.3.1 United States Molecular Diagnostics Infectious Disease Testing Sales Value, 2019-2030
6.3.2 United States Molecular Diagnostics Infectious Disease Testing Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Molecular Diagnostics Infectious Disease Testing Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Molecular Diagnostics Infectious Disease Testing Sales Value, 2019-2030
6.4.2 Europe Molecular Diagnostics Infectious Disease Testing Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Molecular Diagnostics Infectious Disease Testing Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Molecular Diagnostics Infectious Disease Testing Sales Value, 2019-2030
6.5.2 China Molecular Diagnostics Infectious Disease Testing Sales Value by Type (%), 2023 VS 2030
6.5.3 China Molecular Diagnostics Infectious Disease Testing Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Molecular Diagnostics Infectious Disease Testing Sales Value, 2019-2030
6.6.2 Japan Molecular Diagnostics Infectious Disease Testing Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Molecular Diagnostics Infectious Disease Testing Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Molecular Diagnostics Infectious Disease Testing Sales Value, 2019-2030
6.7.2 South Korea Molecular Diagnostics Infectious Disease Testing Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Molecular Diagnostics Infectious Disease Testing Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Molecular Diagnostics Infectious Disease Testing Sales Value, 2019-2030
6.8.2 Southeast Asia Molecular Diagnostics Infectious Disease Testing Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Molecular Diagnostics Infectious Disease Testing Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Molecular Diagnostics Infectious Disease Testing Sales Value, 2019-2030
6.9.2 India Molecular Diagnostics Infectious Disease Testing Sales Value by Type (%), 2023 VS 2030
6.9.3 India Molecular Diagnostics Infectious Disease Testing Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Abbott Laboratories
7.1.1 Abbott Laboratories Profile
7.1.2 Abbott Laboratories Main Business
7.1.3 Abbott Laboratories Molecular Diagnostics Infectious Disease Testing Products, Services and Solutions
7.1.4 Abbott Laboratories Molecular Diagnostics Infectious Disease Testing Revenue (US$ Million) & (2019-2024)
7.1.5 Abbott Laboratories Recent Developments
7.2 BD
7.2.1 BD Profile
7.2.2 BD Main Business
7.2.3 BD Molecular Diagnostics Infectious Disease Testing Products, Services and Solutions
7.2.4 BD Molecular Diagnostics Infectious Disease Testing Revenue (US$ Million) & (2019-2024)
7.2.5 BD Recent Developments
7.3 ²ú¾±´Ç²Ñé°ù¾±±ð³Ü³æ
7.3.1 ²ú¾±´Ç²Ñé°ù¾±±ð³Ü³æ Profile
7.3.2 ²ú¾±´Ç²Ñé°ù¾±±ð³Ü³æ Main Business
7.3.3 ²ú¾±´Ç²Ñé°ù¾±±ð³Ü³æ Molecular Diagnostics Infectious Disease Testing Products, Services and Solutions
7.3.4 ²ú¾±´Ç²Ñé°ù¾±±ð³Ü³æ Molecular Diagnostics Infectious Disease Testing Revenue (US$ Million) & (2019-2024)
7.3.5 Thermo Fisher Scientific Recent Developments
7.4 Thermo Fisher Scientific
7.4.1 Thermo Fisher Scientific Profile
7.4.2 Thermo Fisher Scientific Main Business
7.4.3 Thermo Fisher Scientific Molecular Diagnostics Infectious Disease Testing Products, Services and Solutions
7.4.4 Thermo Fisher Scientific Molecular Diagnostics Infectious Disease Testing Revenue (US$ Million) & (2019-2024)
7.4.5 Thermo Fisher Scientific Recent Developments
7.5 F. Hoffmann-La Roche
7.5.1 F. Hoffmann-La Roche Profile
7.5.2 F. Hoffmann-La Roche Main Business
7.5.3 F. Hoffmann-La Roche Molecular Diagnostics Infectious Disease Testing Products, Services and Solutions
7.5.4 F. Hoffmann-La Roche Molecular Diagnostics Infectious Disease Testing Revenue (US$ Million) & (2019-2024)
7.5.5 F. Hoffmann-La Roche Recent Developments
7.6 Siemens AG
7.6.1 Siemens AG Profile
7.6.2 Siemens AG Main Business
7.6.3 Siemens AG Molecular Diagnostics Infectious Disease Testing Products, Services and Solutions
7.6.4 Siemens AG Molecular Diagnostics Infectious Disease Testing Revenue (US$ Million) & (2019-2024)
7.6.5 Siemens AG Recent Developments
7.7 Veridex
7.7.1 Veridex Profile
7.7.2 Veridex Main Business
7.7.3 Veridex Molecular Diagnostics Infectious Disease Testing Products, Services and Solutions
7.7.4 Veridex Molecular Diagnostics Infectious Disease Testing Revenue (US$ Million) & (2019-2024)
7.7.5 Veridex Recent Developments
7.8 Luminex
7.8.1 Luminex Profile
7.8.2 Luminex Main Business
7.8.3 Luminex Molecular Diagnostics Infectious Disease Testing Products, Services and Solutions
7.8.4 Luminex Molecular Diagnostics Infectious Disease Testing Revenue (US$ Million) & (2019-2024)
7.8.5 Luminex Recent Developments
7.9 GenMark Diagnostics
7.9.1 GenMark Diagnostics Profile
7.9.2 GenMark Diagnostics Main Business
7.9.3 GenMark Diagnostics Molecular Diagnostics Infectious Disease Testing Products, Services and Solutions
7.9.4 GenMark Diagnostics Molecular Diagnostics Infectious Disease Testing Revenue (US$ Million) & (2019-2024)
7.9.5 GenMark Diagnostics Recent Developments
7.10 Qiagen NV
7.10.1 Qiagen NV Profile
7.10.2 Qiagen NV Main Business
7.10.3 Qiagen NV Molecular Diagnostics Infectious Disease Testing Products, Services and Solutions
7.10.4 Qiagen NV Molecular Diagnostics Infectious Disease Testing Revenue (US$ Million) & (2019-2024)
7.10.5 Qiagen NV Recent Developments
7.11 Genomix Biotech
7.11.1 Genomix Biotech Profile
7.11.2 Genomix Biotech Main Business
7.11.3 Genomix Biotech Molecular Diagnostics Infectious Disease Testing Products, Services and Solutions
7.11.4 Genomix Biotech Molecular Diagnostics Infectious Disease Testing Revenue (US$ Million) & (2019-2024)
7.11.5 Genomix Biotech Recent Developments
7.12 BioTheranostics
7.12.1 BioTheranostics Profile
7.12.2 BioTheranostics Main Business
7.12.3 BioTheranostics Molecular Diagnostics Infectious Disease Testing Products, Services and Solutions
7.12.4 BioTheranostics Molecular Diagnostics Infectious Disease Testing Revenue (US$ Million) & (2019-2024)
7.12.5 BioTheranostics Recent Developments
7.13 GenMark Diagnostics
7.13.1 GenMark Diagnostics Profile
7.13.2 GenMark Diagnostics Main Business
7.13.3 GenMark Diagnostics Molecular Diagnostics Infectious Disease Testing Products, Services and Solutions
7.13.4 GenMark Diagnostics Molecular Diagnostics Infectious Disease Testing Revenue (US$ Million) & (2019-2024)
7.13.5 GenMark Diagnostics Recent Developments
8 Industry Chain Analysis
8.1 Molecular Diagnostics Infectious Disease Testing Industrial Chain
8.2 Molecular Diagnostics Infectious Disease Testing Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Molecular Diagnostics Infectious Disease Testing Sales Model
8.5.2 Sales Channel
8.5.3 Molecular Diagnostics Infectious Disease Testing Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Abbott Laboratories
BD
²ú¾±´Ç²Ñé°ù¾±±ð³Ü³æ
Thermo Fisher Scientific
F. Hoffmann-La Roche
Siemens AG
Veridex
Luminex
GenMark Diagnostics
Qiagen NV
Genomix Biotech
BioTheranostics
GenMark Diagnostics
Ìý
Ìý
*If Applicable.
